SCWorx Corp.
No SEC Form 4 filings for $WORX in the last 30 days.
See all $WORX insider activity →Biotech stocks rallied on Monday, with Silence Therapeutics (SLN) up 125% after a $1.3B acquisition by Merck, SCWorx (WORX) up 105% on a new healthcare deal, and Disc Medicine (IRON) up 41% on positive trial results. Actinium (ATNM) and Evaxion (EVAX) also saw gains on clinical updates.
SCWorx Corp. (WORX) has signed a new agreement to provide healthcare supply chain data management services to a community-owned healthcare system in NM, AZ, CO, and UT. The deal represents early validation of SCWorx's market strategy, though specific financial details were not disclosed.
SCWorx Corp. (Nasdaq: WORX) resumed trading on Nasdaq after regaining compliance with listing requirements. The company reported improved operating performance, with Q2 2026 revenue of $706,000 and gross profit up 83% YoY. Net loss declined significantly, and cash usage decreased. SCWorx aims to grow its healthcare customer base and leverage AI for data management.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning WORX (SCWorx Corp.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent WORX coverage spans corporate actions and financial news.
The contract expands recurring revenue and should support near‑term upside.
The contract adds a new customer but lacks disclosed value, limiting immediate market impact.
Likely positive price pressure as the market re‑prices the reinstated listing and improved operating metrics.
The waivers prevent immediate termination of the private placement, supporting the company's capital and listing status.
Potential price appreciation as the stock moves from OTC to Nasdaq.
AlphAI scores every news story that mentions WORX with an AI model for sentiment and relevance, and aggregates insider trades from SCWorx Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Biotech stocks rallied on Monday, with Silence Therapeutics (SLN) up 125% after a $1.3B acquisition by Merck, SCWorx (WORX) up 105% on a new healthcare deal, and Disc Medicine (IRON) up 41% on positive trial results. Actinium (ATNM) and Evaxion (EVAX) also saw gains on clinical updates.
2 min readSCWorx Corp. (WORX) has signed a new agreement to provide healthcare supply chain data management services to a community-owned healthcare system in NM, AZ, CO, and UT. The deal represents early validation of SCWorx's market strategy, though specific financial details were not disclosed.
1 min readSCWorx Corp. (Nasdaq: WORX) resumed trading on Nasdaq after regaining compliance with listing requirements. The company reported improved operating performance, with Q2 2026 revenue of $706,000 and gross profit up 83% YoY. Net loss declined significantly, and cash usage decreased. SCWorx aims to grow its healthcare customer base and leverage AI for data management.
2 min readSCWorx (WORX) secured waivers from private placement investors, preserving $938,000 in financing. The waivers prevent investors from exercising termination rights due to a Nasdaq review, unless the stock is delisted or trading does not resume by October 31, 2026. This action helps maintain sufficient publicly held shares for continued Nasdaq listing.
1 min readSCWorx Corp. (OTCQB: WORX) announced that the Nasdaq Hearings Panel granted its request for reconsideration and approved continued listing on The Nasdaq Capital Market. The decision follows the company's compliance with Nasdaq's minimum bid price and publicly held shares requirements. Trading will resume on Nasdaq once the reinstatement date is confirmed, with conditions including a one-year monitoring period.
1 min readSCWorx Corp. (WORX) filed an SEC Form 8-K — Other Events. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Summary Company Completed Offering to Cure Nasdaq Publicly Held Shares Deficiency and Submitted Request for Reconsideration; Common Stock Continues to Be Quoted on OTCQB
6 min readSCWorx Corp. (WORX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Securities Purchase Agreement On September 16, 2026, SCWorx Corp. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with ten accredited investors (the “Purchasers”), pursuant to which the
1 min readSCWorx Corp. said Nasdaq’s Hearings Panel issued a partial compliance letter confirming completion of the first benchmark in its approved plan to regain compliance for continued listing. The remaining requirement is to meet the Nasdaq minimum bid price of at least $1.00 for 20 consecutive trading days, under Listing Rule 5815(c)(4).
2 min readSCWorx Corp. (WORX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001674227 0001674227 2026-07-22 2026-07-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
2 min readSCWorx Corp. has announced a 1-for-15 reverse stock split, effective April 10, 2026, to combine every 15 shares of its common stock into one. This action is intended to help the company regain compliance with Nasdaq’s minimum bid price rule of $1.00 per share. However, SCWorx noted there is no guarantee this will prevent potential delisting from the Nasdaq Stock Market.
4 min read
